Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celon PharmaLTS:0RKX 21 Return-on-Tangible-Asset is 117.52% as of Mar. 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Celon Pharma ranks better than 94.74% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Celon Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was zł650.4 Mil. Celon Pharma's average total tangible assets for the quarter that ended in Mar. 2026 was zł553.4 Mil. Therefore, Celon Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 117.52%.
The historical rank and industry rank for Celon Pharma's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0RKX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -15.85 Med: -1.1 Max: 21.12
Current: 21.12
During the past 11 years, Celon Pharma's highest Return-on-Tangible-Asset was 21.12%. The lowest was -15.85%. And the median was -1.10%.
LTS:0RKX's Return-on-Tangible-Asset is ranked better than 94.74% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.14
vs LTS:0RKX: 21.12
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Celon Pharma Return-on-Tangible-Asset Related Terms
Celon Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKX vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 117.52% mean?
Celon Pharma (LTS:0RKX) has a Return-on-Tangible-Asset of 117.52% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #53 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Celon Pharma's Return-on-Tangible-Asset too high?
Celon Pharma's current Return-on-Tangible-Asset is 117.52%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.14. Celon Pharma's value of 117.52% is 3642.7% above this industry median. Based on the distribution chart, Celon Pharma ranks #53 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #53 out of 1008 companies for Return-on-Tangible-Asset. This places Celon Pharma in the top 5% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.14. Celon Pharma's value of 117.52% is 3642.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.14, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current Return-on-Tangible-Asset of 117.52% is 3642.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Return-on-Tangible-Asset is 117.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Return-on-Tangible-Asset of 117.52%. The current Return-on-Tangible-Asset is 117.52% and 3642.7% above the Drug Manufacturers industry median of 3.14. Celon Pharma's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Return-on-Tangible-Asset is 117.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
21GF Score
Get the complete analysis for LTS:0RKX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 
